ANTIGEN-BINDING PROTEINS TARGETING S. AUREUS ORF0657n

The present invention features antigen binding proteins that bind to a region found to have an epitope that can be targeted to provide protection against S. aureus infection. The region is designated herein as the CS-D7 target region. The CS-D7 target region provides an S. aureus ORF0657n epitope that can be targeted to reduce the likelihood or severity of an S. aureus infection.

Methods of treating metastasis, including inhibiting bone cancer metastasis, by administering an antibody which binds connexin 43 (Cx43) hemichannel

Antibodies that bind to connexin 43 hemichannels and inhibit, or activate, channel opening are provided. In certain aspects, methods for detecting or treating cancers with antibodies that activate Cx43 channel opening are also provided. Likewise, methods for treating inflammatory diseases (e.g., osteoarthritis) and neurological injuries (e.g., spinal cord injury) with antibodies that inhibit Cx43 channel opening are provided.

CMV neutralizing antigen binding proteins

The present invention is directed to antigen binding proteins including, but not limited to, monoclonal antibodies and antigen binding fragments thereof, that specifically bind to and preferably neutralize human cytomegalovirus (CMV). Also encompassed by the invention are antigen binding proteins that have been humanized. The antigen binding proteins of the invention are useful as a therapeutic agent for treating and/or preventing CMV infections in a patient in need thereof.

CMV NEUTRALIZING ANTIGEN BINDING PROTEINS

A supercritical extractor system may include extractor chambers coupled to a supercritical fluid pump and configured to receive a matrix for an extraction process and a supercritical fluid from the supercritical fluid pump, and evaporator chambers coupled to the extractor chambers and configured to output an extractant from the matrix. Each evaporator chamber may include a body defining a cavity, a cone within the cavity, and arms coupled between an inner surface of the body and the cone. The supercritical extractor system may include a condenser coupled between the evaporator chambers and the supercritical fluid reservoir, and a controller coupled to the supercritical fluid pump, the extractor chambers, and the evaporator chambers and configured to monitor a characteristic during the extraction process. 1. A supercritical extractor system comprising:a supercritical fluid reservoir configured to store a supercritical fluid;a supercritical fluid pump coupled to said supercritical fluid reservoir;a plurality of extractor chambers coupled to said supercritical fluid pump and configured to receive a matrix for an extraction process and the supercritical fluid from said supercritical fluid pump; a body defining a cavity therein,', 'at least one cone within the cavity, and', 'a plurality of arms coupled between an inner surface of said body and said at least one cone;, 'a plurality of evaporator chambers coupled to said plurality of said extractor chambers and configured to output an extractant from the matrix, each evaporator chamber comprising'}a condenser coupled between said plurality of evaporator chambers and said supercritical fluid reservoir; anda controller coupled to said supercritical fluid pump, said plurality of extractor chambers, and said plurality of evaporator chambers and configured to monitor at least one characteristic during the extraction process.2. The supercritical extractor system of wherein the supercritical fluid comprises supercritical CO.3. ...

Anti-ADDL Antibodies and Uses Thereof

The present invention relates to antibodies that differentially recognize multi-dimensional conformations of Aβ-derived diffusible ligands, also known as ADDLs. The antibodies of the invention can distinguish between Alzheimer's Disease and control human brain extracts and are useful in methods of detecting ADDLs and diagnosing Alzheimer's Disease. The present antibodies also block binding of ADDLs to neurons, assembly of ADDLs, and tau phosphorylation and are there useful in methods for the preventing and treating diseases associated with soluble oligomers of amyloid β 1-42.

Endotrophin neutralization and use thereof

Aspects of the present invention relate to methods and reagents for increasing chemosensitivity to platinum-based chemotherapy. In one aspect, a method of increasing chemosensitivity to platinum-based chemotherapy is provided, comprising administering to a patient in need thereof an effective amount of an endotrophin-neutralizing agent. The agent can be a monoclonal antibody, or fragment thereof, capable of binding to the C5 domain of the alpha3 chain of collagen VI. In some embodiments, the method can further include administering an effective amount of thiazolidinedione to said patient.

CMV neutralizing antigen binding proteins

The present invention is directed to antigen binding proteins including, but not limited to, monoclonal antibodies and antigen binding fragments thereof, that specifically bind to and preferably neutralize human cytomegalovirus (CMV). The antigen binding proteins of the invention are useful as a prophylactic and/or therapeutic agent for preventing and/or treating CMV infections in a patient in need thereof. Also encompassed by the invention are pharmaceutical compositions comprising the antigen binding proteins of the invention and a pharmaceutically acceptable carrier. The invention further relates to methods of using the antigen binding proteins and pharmaceutical compositions of the invention for the prevention or treatment of CMV infection in patients in need thereof.

Antibodies specific for DKK-1

Antibodies specific for Dkk-1, an inhibitor of the osteoanabolic Wnt/LRP5 signaling pathway, are described. The antibodies, which inhibit binding of Dkk-1 to LRP5, are useful in compositions for stimulating bone growth, in particular, compositions for treating bone disorders which result in a loss in bone, for example, osteoporosis.

Anti-ADDL monoclonal antibody and use thereof

The present invention relates to antibodies that differentially recognize multi-dimensional conformations of A-derived diffusible ligands, also known as ADDLs. The antibodies of the invention can distinguish between Alzheimer's Disease and control human brain extracts and are useful in methods of detecting ADDLs and diagnosing Alzheimer's Disease. The present antibodies also block binding of ADDLs to neurons, assembly of ADDLS, and tau phosphorylation and are there useful in methods for the preventing and treating diseases associated with soluble oligomers of amyloid 1-42.

Anti-ADDL monoclonal antibody and use thereof

The present invention relates to antibodies that differentially recognize multi-dimensional conformations of A-derived diffusible ligands, also known as ADDLs. The antibodies of the invention can distinguish between Alzheimer's Disease and control human brain extracts and are useful in methods of detecting ADDLs and diagnosing Alzheimer's Disease. The present antibodies also block binding of ADDLs to neurons, assembly of ADDLS, and tau phosphorylation and are there useful in methods for the preventing and treating diseases associated with soluble oligomers of amyloid 1-42.

High affinity antibody antagonists of interleukin-13 receptor alpha 1

High affinity antibody antagonists of human interleukin-13 receptor alpha 1 are disclosed. The antibody molecules are effective in the inhibition of IL-13Rα1-mediated activities and, accordingly, present desirable antagonists for the use in the treatment of conditions associated with hIL-13Rα1 activity. The present invention also discloses nucleic acid encoding said antibody molecules, vectors, host cells, and compositions comprising the antibody molecules. Methods of using the antibody molecules for inhibiting or antagonizing IL-13Rα1-mediated activities are also disclosed.

Anti-IL-13R Alpha1 Antibodies and Their Uses Thereof

Antibody antagonists of human interleukin-13 receptor alpha 1 which bind to hIL-13Rα1 through domain 3 of the extracellular region of the receptor and inhibit IL-13 receptor-mediated signaling by IL-13 are disclosed herein. These antibodies have uses inter alia in the treatment or prevention of IL-13-related disorders and diseases. The present invention also discloses nucleic acid encoding said antibody molecules, vectors, host cells, and compositions comprising the antibody molecules. Methods of using the antibody molecules for inhibiting or antagonizing hIL-13Rα1-mediated activities are also disclosed.

HER3 specific monoclonal antibodies for diagnostic and therapeutic use

Isolated or recombinant anti-HER3 monoclonal antibodies are provided. In some cases, antibodies of the embodiments can be used for the detection, diagnosis and/or therapeutic treatment of human diseases, such as cancer.

Anti-ADDL antibodies and uses thereof

The present invention relates to antibodies that differentially recognize multi-dimensional conformations of Aβ-derived diffusible ligands, also known as ADDLs. The antibodies of the invention can distinguish between Alzheimer's Disease and control human brain extracts and are useful in methods of detecting ADDLs and diagnosing Alzheimer's Disease. The present antibodies also block binding of ADDLs to neurons, assembly of ADDLS, and tau phosphorylation and are there useful in methods for the preventing and treating diseases associated with soluble oligomers of amyloid β1-42.

Anti-ADDL antibodies and uses thereof

The present invention relates to antibodies that differentially recognize multi-dimensional conformations of A-derived diffusible ligands, also known as ADDLs. The antibodies of the invention can distinguish between Alzheimer's Disease and control human brain extracts and are useful in methods of detecting ADDLs and diagnosing Alzheimer's Disease. The present antibodies also block binding of ADDLs to neurons, assembly of ADDLS, and tau phosphorylation and are there useful in methods for the preventing and treating diseases associated with soluble oligomers of amyloid 1-42.

Anti-leukocyte-associated immunoglobulin-like receptor 1 (LAIR1) monoclonal antibodies and method of use thereof to treat cancer

The present disclosure is directed to antibodies binding to LAIR 1 and their treating cancer, inflammation, immune-related diseases or transplantation.

Anti-addl antibodies and uses thereof

The present invention relates to antibodies that differentially recognize multi-dimensional conformations of Aβ-derived diffusible ligands, also known as ADDLs. The antibodies of the invention can distinguish between Alzheimer's Disease and control human brain extracts and are useful in methods of detecting ADDLs and diagnosing Alzheimer's Disease. The present antibodies also block binding of ADDLs to neurons, assembly of ADDLs, and tauphosphorylation and are there useful in methods for the preventing and treating diseases associated with soluble oligomers of amyloid β 1-42.

Anti-ADDL antibodies and uses thereof

The present invention relates to antibodies that differentially recognize multi-dimensional conformations of Aβ-derived diffusible ligands, also known as ADDLs. The antibodies of the invention can distinguish between Alzheimer's Disease and control human brain extracts and are useful in methods of detecting ADDLs and diagnosing Alzheimer's Disease. The present antibodies also block binding of ADDLs to neurons, assembly of ADDLS, and tau phosphorylation and are there useful in methods for the preventing and treating diseases associated with soluble oligomers of amyloid β 1-42.

Anti-ADDL antibodies and uses thereof

The present invention relates to antibodies that differentially recognize multi-dimensional conformations of A-derived diffusible ligands, also known as ADDLs. The antibodies of the invention can distinguish between Alzheimer's Disease and control human brain extracts and are useful in methods of detecting ADDLs and diagnosing Alzheimer's Disease. The present antibodies also block binding of ADDLs to neurons, assembly of ADDLs, and tau phosphorylation and are there useful in methods for the preventing and treating diseases associated with soluble oligomers of amyloid 1-42.

Anti-ADDL monoclonal antibody and use thereof

The present invention relates to antibodies that differentially recognize multi-dimensional conformations of Aβ-derived diffusible ligands, also known as ADDLs. The antibodies of the invention can distinguish between Alzheimer's Disease and control human brain extracts and are useful in methods of detecting ADDLs and diagnosing Alzheimer's Disease. The present antibodies also block binding of ADDLs to neurons, assembly of ADDLs, and tau phosphorylation and are there useful in methods for the preventing and treating diseases associated with soluble oligomers of amyloid β 1-42.

Endotrophin neutralization and use thereof

Aspects of the present invention relate to methods and reagents for increasing chemosensitivity to platinum-based chemotherapy. In one aspect, a method of increasing chemosensitivity to platinum-based chemotherapy is provided, comprising administering to a patient in need thereof an effective amount of an endotrophin-neutralizing agent. The agent can be a monoclonal antibody, or fragment thereof, capable of binding to the C5 domain of the alpha3 chain of collagen VI. In some embodiments, the method can further include administering an effective amount of thiazolidinedione to said patient.

Anti-ADDL Antibodies and Uses Thereof

The present invention relates to antibodies that differentially recognize multi-dimensional conformations of A-derived diffusible ligands, also known as ADDLs. The antibodies of the invention can distinguish between Alzheimer's Disease and control human brain extracts and are useful in methods of detecting ADDLs and diagnosing Alzheimer's Disease. The present antibodies also block binding of ADDLs to neurons, assembly of ADDLS, and tau phosphorylation and are there useful in methods for the preventing and treating diseases associated with soluble oligomers of amyloid 1-42.

Anti-ADDL Antibodies and Uses Thereof

The present invention relates to antibodies that differentially recognize multi-dimensional conformations of Aβ-derived diffusible ligands, also known as ADDLs. The antibodies of the invention can distinguish between Alzheimer's Disease and control human brain extracts and are useful in methods of detecting ADDLs and diagnosing Alzheimer's Disease. The present antibodies also block binding of ADDLs to neurons, assembly of ADDLS, and tau phosphorylation and are there useful in methods for the preventing and treating diseases associated with soluble oligomers of amyloid β 1-42. 1. An isolated antibody , or an antigen binding fragment of the antibody , that binds amyloid β-derived diffusible ligands comprising: (i) a CDR1 of SEQ ID NO:52 or SEQ ID NO:53;', '(ii) a CDR2 of SEQ ID NO:57 or SEQ ID NO:58; and', '(iii) a CDR3 of SEQ ID NO:65 or SEQ ID NO:66; and, '(a) a light chain variable region comprising,'} (i) a CDR1 of SEQ ID NO: 27 or SEQ ID NO:28,', '(ii) a CDR2 of SEQ ID NO:32 or SEQ ID NO:37, and', '(iii) a CDR3 of SEQ ID NO:42, SEQ ID NO:44, SEQ ID NO:45, SEQ ID NO:46, or SEQ ID NO:47., '(b) a heavy chain variable region comprising,'}2. The isolated antibody of claim 1 , further comprising a heavy chain constant region of SEQ ID NO:137.3. The isolated antibody of claim 1 , wherein the antibody is a monoclonal antibody.4. A pharmaceutical composition comprising the antibody or antigen binding fragment of in admixture with a pharmaceutically acceptable carrier.5. A method for attenuating binding of Aβ-derived diffusible ligands to a neuron comprising contacting the neuron with the antibody or antigen binding fragment of so that binding of Aβ-derived diffusible ligands to the neuron is attenuated.6. A method for inhibiting assembly of Aft-derived diffusible ligands comprising contacting a sample containing amyloid β 1-42 peptides with the antibody or antigen binding fragment of thereby inhibiting assembly of Aβ-derived diffusible ligands.7. A method for inhibiting ...

Antibody Antagonists of Interleukin-13 Receptor Alpha1

Antibody antagonists of human interleukin-13 receptor alpha 1 are disclosed. The antibody molecules are useful in the inhibition of IL-13Rα1-mediated activities and, accordingly, present desirable antagonists for the use in the treatment of conditions associated with hIL-13Rα1 activity. The present invention also discloses nucleic acid encoding said antibody molecules, vectors, host cells, and compositions comprising the antibody molecules. Methods of using the antibody molecules for inhibiting or antagonizing IL-13Rα1-mediated activities are also disclosed.

High affinity antibody antagonists of interleukin-13 receptor alpha 1

High affinity antibody antagonists of human interleukin-13 receptor alpha 1 are disclosed. The antibody molecules are effective in the inhibition of IL-13Ralpha1-mediated activities and, accordingly, present desirable antagonists for the use in the treatment of conditions associated with hIL-13Ralpha1 activity. The present invention also discloses nucleic acid encoding said antibody molecules, vectors, host cells, and compositions comprising the antibody molecules. Methods of using the antibody molecules for inhibiting or antagonizing IL-13Ralpha1-mediated activities are also disclosed.

CONNEXIN (CX) 43 HEMICHANNEL-BINDING ANTIBODIES AND USES THEREOF

Antibodies that bind to connexin 43 hemichannels and inhibit, or activate, channel opening are provided. In certain aspects, methods for detecting or treating cancers with antibodies that activate Cx43 channel opening are also provided. Likewise, methods for treating inflammatory diseases (e.g., osteoarthritis) and neurological injuries (e.g., spinal cord injury) with antibodies that inhibit Cx43 channel opening arc provided. 1. A method of treating a metastasis in a subject , the method comprising administering to the subject an effective amount of an antibody that binds to a connexin 43 (Cx43) hemichannel and enhances channel opening.2. (canceled)3. (canceled)4. The method of claim 1 , wherein the metastasis is a bone metastasis.5. (canceled)6. (canceled)7. The method of claim 1 , wherein the subject has breast cancer claim 1 , prostate cancer claim 1 , or osteosarcoma.8. The method of claim 1 , wherein the antibody is administered in a pharmaceutically acceptable composition.9. (canceled)10. The method of claim 1 , wherein the antibody is administered intravenously claim 1 , intradermally claim 1 , intratumorally claim 1 , intramuscularly claim 1 , intraperitoneally claim 1 , subcutaneously claim 1 , or locally.11. The method of claim 1 , wherein the antibody comprises:(a) a first VH CDR identical to SEQ ID NO: 19;(b) a second VH CDR identical to SEQ ID NO: 20;3382738 Page 2 of 5(c) a third VH CDR identical to SEQ ID NO: 21;(d) a first VL CDR identical to SEQ ID NO: 49;(e) a second VL CDR identical to SEQ ID NO: 50; and(f) a third VL CDR identical to SEQ ID NO: 51.12. The method of claim 11 , wherein the antibody is a humanized antibody.13. The method of claim 1 , further comprising administering an anticancer therapy to the subject.14. The method of claim 13 , wherein the anticancer therapy is a surgical therapy claim 13 , chemotherapy claim 13 , radiation therapy claim 13 , cryotherapy claim 13 , hormonal therapy claim 13 , immunotherapy or cytokine therapy. ...

High affinity antibody antagonists of interleukin-13 receptor alpha 1

High affinity antibody antagonists of human interleukin-13 receptor alpha 1 are disclosed. The antibody molecules are effective in the inhibition of IL-13Rα1-mediated activities and, accordingly, present desirable antagonists for the use in the treatment of conditions associated with hIL-13Rα1 activity. The present invention also discloses nucleic acid encoding said antibody molecules, vectors, host cells, and compositions comprising the antibody molecules. Methods of using the antibody molecules for inhibiting or antagonizing IL-13Rα1-mediated activities are also disclosed.

Leptin Antibodies

Antibody antigen binding domains which specifically binds human leptin comprises Vor VCDR1, CDR2 and CDR3 sequences of an hLept antibody. The antibody antigen binding domains and antibodies thereof are useful to treat obesity and diabetes. 2. The antibody antigen binding domain of comprising the Vand VCDR1 claim 1 , CDR2 and CDR3 sequences of the hLept antibody.4. The antibody antigen binding domain of comprising the Vand Vsequences of the hLept antibody.5. The antibody antigen binding domain of wherein the hLept antibody is hLept-1.6. The antibody antigen binding domain of wherein the hLept antibody is hLept-2.7. The antibody antigen binding domain of wherein the hLept antibody is hLept-3.8. The antibody antigen binding domain of wherein the hLept antibody is hLept-5.9. The antibody antigen binding domain of wherein the hLept antibody is hLept-6.10. The antibody antigen binding domain of configured as part of a monoclonal IgG antibody.11. The antibody antigen binding domain of configured as part of a humanised antibody.12. An expression vector encoding the antibody antigen binding domain of .13. A cultured cell expressing the antibody antigen binding domain of .14. A method of using the antibody antigen binding domain of to treat obesity or diabetes claim 1 , comprising the step of administering the domain to a person in need thereof. A Sequence Listing in text format is incorporated by reference into the specification. The name of the text file containing the Sequence Listing is 17124481.txt. The text file is about 24 KB, was created on Mar. 12, 2021, and is being submitted electronically via EFS-Web.Leptin is a hormone produced by adipocytes and is elevated in obesity. The congenital lack of leptin results in obesity and the metabolism field widely accepts the concept. Upon cloning of the leptin gene, the original hope was that leptin would act as a break for further food intake and a trigger to increase energy expenditure. The hope was that the injection of ...

Antibodies specific for Dkk-1

Antibodies specific for Dkk-1, an inhibitor of the osteoanabolic Wnt/LRP5 signaling pathway, are described. The antibodies, which inhibit binding of Dkk-1 to LRP5, are useful in compositions for stimulating bone growth, in particular, compositions for treating bone disorders which result in a loss in bone, for example, osteoporosis.

CMV NEUTRALIZING ANTIGEN BINDING PROTEINS

The present invention is directed to antigen binding proteins including, but not limited to, monoclonal antibodies and antigen binding fragments thereof, that specifically bind to and preferably neutralize human cytomegalovirus (CMV). Also encompassed by the invention are antigen binding proteins that have been humanized. The antigen binding proteins of the invention are useful as a therapeutic agent for treating and/or preventing CMV infections in a patient in need thereof. 3. The recombinant antigen binding protein of claim 1 , wherein the antigen binding protein is a humanized antibody.4. The recombinant antigen binding protein of wherein the light chain variable region domain is selected from the group consisting of SEQ ID NOs:631 claim 1 , 632 claim 1 , 635 claim 1 , 636 claim 1 , 639 claim 1 , 640 claim 1 , 642 and 643.5. The recombinant antigen binding protein of wherein the light chain variable region further comprises a FR1 claim 1 , FR2 claim 1 , FR3 and FR4 selected from the group consisting of:(a) the CDR1, CDR2 and CDR 3 of (1-a) and a FR1 comprising SEQ ID NO:271, a FR2 comprising SEQ ID NO:272, a FR3 comprising SEQ ID NO:361 and a FR4 comprising SEQ ID NO:362;(b) the CDR1, CDR2 and CDR 3 of (1-b) and a FR1 comprising SEQ ID NO:273, a FR2 comprising SEQ ID NO:274, a FR3 comprising SEQ ID NO:363 and a FR4 comprising SEQ ID NO:364;(c) the CDR1, CDR2 and CDR 3 of (1-c) and a FR1 comprising SEQ ID NO:275, a FR2 comprising SEQ ID NO:276, a FR3 comprising SEQ ID NO:365 and a FR4 comprising SEQ ID NO:366;(d) the CDR1, CDR2 and CDR 3 of (1-d) and a FR1 comprising SEQ ID NO:277, a FR2 comprising SEQ ID NO:278, a FR3 comprising SEQ ID NO:367 and a FR4 comprising SEQ ID NO:368;(e) the CDR1, CDR2 and CDR 3 of (1-e) and a FR1 comprising SEQ ID NO:279, a FR2 comprising SEQ ID NO:280, a FR3 comprising SEQ ID NO:369 and a FR4 comprising SEQ ID NO:370;(f) the CDR1, CDR2 and CDR 3 of (1-f) and a FR1 comprising SEQ ID NO:281, a FR2 comprising SEQ ID NO:282, a FR3 ...

High affinity antibody antagonists of interleukin-13 receptor alpha 1

High affinity antibody antagonists of human interleukin-13 receptor alpha 1 are disclosed. The antibody molecules are effective in the inhibition of IL-13R1-mediated activities and, accordingly, present desirable antagonists for the use in the treatment of conditions associated with hIL-13R1 activity. The present invention also discloses nucleic acid encoding said antibody molecules, vectors, host cells, and compositions comprising the antibody molecules. Methods of using the antibody molecules for inhibiting or antagonizing IL-13R1-mediated activities are also disclosed.

HER3 specific monoclonal antibodies for diagnostic and therapeutic use

Isolated or recombinant anti-HER3 monoclonal antibodies are provided. In some cases, antibodies of the embodiments can be used for the detection, diagnosis and/or therapeutic treatment of human diseases, such as cancer.

High affinity antibody antagonists of interleukin-13 receptor alpha 1

High affinity antibody antagonists of human interleukin-13 receptor alpha 1 are disclosed. The antibody molecules are effective in the inhibition of IL-13Rα1-mediated activities and, accordingly, present desirable antagonists for the use in the treatment of conditions associated with hIL-13Rα1 activity. The present invention also discloses nucleic acid encoding said antibody molecules, vectors, host cells, and compositions comprising the antibody molecules. Methods of using the antibody molecules for inhibiting or antagonizing IL-13Rα1-mediated activities are also disclosed.

ANTIBODIES SPECIFIC FOR DKK-1

Antibodies specific for Dkk-1, an inhibitor of the osteoanabolic Wnt/LRP5 signaling pathway, are described. The antibodies, which inhibit binding of Dkk-1 to LRP5, are useful in compositions for stimulating bone growth, in particular, compositions for treating bone disorders which result in a loss in bone, for example, osteoporosis.

Anti-LILRB antibodies and their use in detecting and treating cancer

The present disclosure is directed to antibodies binding to LILRBs and methods of detecting and treating cancer therewith.

HER3 specific monoclonal antibodies for diagnostic and therapeutic use

Isolated or recombinant anti-HER3 monoclonal antibodies are provided. In some cases, antibodies of the embodiments can be used for the detection, diagnosis and/or therapeutic treatment of human diseases, such as cancer.

High Affinity Antibody Antagonists of Interleukin-13 Receptor Alpha 1

High affinity antibody antagonists of human interleukin-13 receptor alpha 1 are disclosed. The antibody molecules are effective in the inhibition of IL-13Rα1-mediated activities and, accordingly, present desirable antagonists for the use in the treatment of conditions associated with hIL-13Rα1 activity. The present invention also discloses nucleic acid encoding said antibody molecules, vectors, host cells, and compositions comprising the antibody molecules. Methods of using the antibody molecules for inhibiting or antagonizing IL-13Rα1-mediated activities are also disclosed.

CONNEXIN (CX) 43 HEMICHANNEL-BINDING ANTIBODIES AND USES THEREOF

Antibodies that bind to connexin 43 hemichannels and inhibit, or activate, channel opening are provided. In certain aspects, methods for detecting or treating cancers with antibodies that activate Cx43 channel opening are also provided. Likewise, methods for treating inflammatory diseases (e.g., osteoarthritis) and neurological injuries (e.g., spinal cord injury) with antibodies that inhibit Cx43 channel opening are provided. 1. A method of treating or preventing osteoporosis , osteopenia or cancer in a subject , the method comprising administering to the subject an effective amount of an antibody or variant thereof that binds to a connexin 43 (Cx43) hemichannel and enhances channel opening or an expression vector encoding the antibody.26.-. (canceled)7. The method of claim 1 , wherein the cancer is breast cancer claim 1 , prostate cancer claim 1 , osteosarcoma or a metastatsis.8. The method of claim 1 , wherein the antibody or the expression vector encoding the antibody is administered in a pharmaceutically acceptable composition.9. (canceled)10. The method of claim 1 , wherein the antibody is administered intravenously claim 1 , intradermally claim 1 , intratumorally claim 1 , intramuscularly claim 1 , intraperitoneally claim 1 , subcutaneously claim 1 , or locally.11. The method of claim 1 , wherein the antibody comprises:(a) a first VH CDR identical to SEQ ID NO: 19;(b) a second VH CDR identical to SEQ ID NO: 20;(c) a third VH CDR identical to SEQ ID NO: 21;(d) a first VL CDR identical to SEQ ID NO: 49;(e) a second VL CDR identical to SEQ ID NO: 50; and(f) a third VL CDR identical to SEQ ID NO: 51.12. The method of claim 11 , wherein the antibody is a humanized antibody.13. (canceled)14. (canceled)15. A method of treating or preventing an inflammatory disease claim 11 , a neurodegenerative disease or a neurological injury in a subject claim 11 , the method comprising administering to the subject an effective amount of an antibody or variant thereof that binds to ...

Anti-LILRB antibodies and their use in detecting and treating cancer

The present disclosure is directed to antibodies binding to LILRBs and methods of detecting and treating cancer therewith.

Anti-ADDL monoclonal antibody and use thereof

The present invention relates to antibodies that differentially recognize multi-dimensional conformations of Aβ-derived diffusible ligands, also known as ADDLs. The antibodies of the invention can distinguish between Alzheimer's Disease and control human brain extracts and are useful in methods of detecting ADDLs and diagnosing Alzheimer's Disease. The present antibodies also block binding of ADDLs to neurons, assembly of ADDLS, and tau phosphorylation and are there useful in methods for the preventing and treating diseases associated with soluble oligomers of amyloid β 1-42.

Methods for identifying LILRB-blocking antibodies

Provided herein are methods and compositions for the identification of modulators of ApoE-induced LILRB activation. Also provided herein are methods of treating cancer comprising the administration of an inhibitor of ApoE-induced LILRB activation. Also provided are methods of treating autoimmune disease or inhibiting the onset of transplant rejection or treating an inflammatory disorder comprising administering an agonist of ApoE-induced LILRB activation to a subject.

HIGH AFFINITY ANTIBODY ANTAGONISTS OF INTERLEUKIN-13 RECEPTOR ALPHA 1

High affinity antibody antagonists of human interleukin-13 receptor alpha 1 are disclosed. The antibody molecules are effective in the inhibition of IL-13Rα1-mediated activities and, accordingly, present desirable antagonists for the use in the treatment of conditions associated with hIL-13Rα1 activity. The present invention also discloses nucleic acid encoding said antibody molecules, vectors, host cells, and compositions comprising the antibody molecules. Methods of using the antibody molecules for inhibiting or antagonizing IL-13Rα1-mediated activities are also disclosed. 1. An isolated antibody that binds to human interleukin 13 receptor alpha 1 , comprising:(a) a heavy chain variable region comprising comprises CDR1, CDR2, and CDR3 amino acid sequences as set forth in SEQ ID NO:82, SEQ ID NO:83, and SEQ ID NO:7, respectively; and (b) a light chain variable region comprising comprises CDR1, CDR2, and CDR3 amino acid sequences as set forth in SEQ ID NO:84, SEQ ID NO:85, and SEQ ID NO:38, respectively.2. The isolated antibody of claim 1 , wherein the heavy chain variable region has the amino acid sequence as set forth in SEQ ID NO:63 and the light chain variable region has the amino acid sequence set forth in SEQ ID NO:71.3. A composition comprising the antibody of and a pharmaceutically acceptable carrier.4. A composition comprising the antibody of and a pharmaceutically acceptable carrier. This application is a continuation of U.S. Ser. No. 12/774,966 filed May 6, 2010, which is a continuation of U.S. Ser. No. 11/875,017 filed Oct. 19, 2007, now issued as U.S. Pat. No. 7,754,213, which claims benefit of priority to U.S. Provisional Patent Application Ser. No. 60/852,884, filed Oct. 19, 2006, each of which are herein incorporated by reference in their entireties.Data from human studies and experimental animal models strongly implicate Th2-derived cytokines as contributing to atopic asthma, with interleukin-4 (IL-4) and interleukin-13 (IL-13; see, e.g., Minty et ...

Leptin antibodies

Antibody antigen binding domains which specifically binds human leptin comprises VHor VLCDR1, CDR2 and CDR3 sequences of an hLept antibody. The antibody antigen binding domains and antibodies thereof are useful to treat obesity and diabetes.

Anti-ADDL antibodies and uses thereof

The present invention relates to antibodies that differentially recognize multi-dimensional conformations of Aβ-derived diffusible ligands, also known as ADDLs. The antibodies of the invention can distinguish between Alzheimer's Disease and control human brain extracts and are useful in methods of detecting ADDLs and diagnosing Alzheimer's Disease. The present antibodies also block binding of ADDLs to neurons, assembly of ADDLS, and tau phosphorylation and are there useful in methods for the preventing and treating diseases associated with soluble oligomers of amyloid β 1-42.

High affinity antibody antagonists of interleukin-13 receptor alpha 1

High affinity antibody antagonists of human interleukin-13 receptor alpha 1 are disclosed. The antibody molecules are effective in the inhibition of IL-13R1-mediated activities and, accordingly, present desirable antagonists for the use in the treatment of conditions associated with hIL-13R1 activity. The present invention also discloses nucleic acid encoding said antibody molecules, vectors, host cells, and compositions comprising the antibody molecules. Methods of using the antibody molecules for inhibiting or antagonizing IL-13R1-mediated activities are also disclosed.

EGFL6 specific monoclonal antibodies and methods of their use

Isolated or recombinant anti-EGFL6 monoclonal antibodies are provided. In some cases, antibodies of the embodiments can be used for the detection, diagnosis and/or therapeutic treatment of human diseases, such as cancer.

Methods of treating an osteolytic tumor and spinal cord injury by administering connexin (Cx) 43 hemichannel-binding antibodies

Antibodies that bind to connexin 43 hemichannels and inhibit, or activate, channel opening are provided. In certain aspects, methods for detecting or treating cancers with antibodies that activate Cx43 channel opening are also provided. Likewise, methods for treating inflammatory diseases (e.g., osteoarthritis) and neurological injuries (e.g., spinal cord injury) with antibodies that inhibit Cx43 channel opening are provided.

HIGH AFFINITY ANTIBODY ANTAGONISTS OF INTERLEUKIN-13 RECEPTOR ALPHA 1

High affinity antibody antagonists of human interleukin-13 receptor alpha 1 are disclosed. The antibody molecules are effective in the inhibition of IL-13Rα1-mediated activities and, accordingly, present desirable antagonists for the use in the treatment of conditions associated with hIL-13α1 activity. The present invention also discloses nucleic acid encoding said antibody molecules, vectors, host cells, and compositions comprising the antibody molecules. Methods of using the antibody molecules for inhibiting or antagonizing IL-13Rα1-mediated activities are also disclosed. 1. An isolated nucleic acid molecule encoding an antibody that binds to human interleukin 13 receptor alpha 1 , comprising:(a) a heavy chain variable region comprising CDR1, CDR2, and CDR3 amino acid sequences as set forth in SEQ ID NO:82, SEQ ID NO:83, and SEQ ID NO:7, respectively; and(b) a light chain variable region comprising CDR1, CDR2, and CDR3 amino acid sequences as set forth in SEQ ID NO:84, SEQ ID NO:85, and SEQ ID NO:38, respectively.2. The isolated nucleic acid molecule of claim 1 , wherein the heavy chain variable region has the amino acid sequence as set forth in SEQ ID NO:63 and the light chain variable region has the amino acid sequence set forth in SEQ ID NO:71.3. A vector comprising the nucleic acid molecule of .4. A vector comprising the nucleic acid molecule of .5. A host cell harboring the nucleic acid molecule of .6. A host cell harboring the nucleic acid molecule of .7. A host cell harboring the vector of .8. A host cell harboring the vector of .9. A method for making an antibody that binds to human interleukin 13 receptor alpha 1 claim 4 , comprising:{'claim-ref': {'@idref': 'CLM-00001', 'claim 1'}, '(a) incubating a cell harboring a nucleic acid molecule of under conditions that allow expression and assembly of the heavy and light chain variable regions into an antibody molecule; and'}(b) isolating the antibody from the cell.10. A method for making an antibody that binds ...

Antibody antagonists of interleukin-13 receptor 1

Antibody antagonists of human interleukin-13 receptor alpha 1 are disclosed. The antibody molecules are useful in the inhibition of IL-13Rα1-mediated activities and, accordingly, present desirable antagonists for the use in the treatment of conditions associated with hIL-13Rα activity. The present invention also discloses nucleic acid encoding said antibody molecules, vectors, host cells, and compositions comprising the antibody molecules. Methods of using the antibody molecules for inhibiting or antagonizing IL-13Rα1-mediated activities are also disclosed.

HIGH AFFINITY ANTIBODY ANTAGONISTS OF INTERLEUKIN-13 RECEPTOR ALPHA 1

High affinity antibody antagonists of human interleukin-13 receptor alpha 1 are disclosed. The antibody molecules are effective in the inhibition of IL-13Rα1-mediated activities and, accordingly, present desirable antagonists for the use in the treatment of conditions associated with hIL-13Rα1 activity. The present invention also discloses nucleic acid encoding said antibody molecules, vectors, host cells, and compositions comprising the antibody molecules. Methods of using the antibody molecules for inhibiting or antagonizing IL-13Rα1-mediated activities are also disclosed. 1. A method for ameliorating a condition caused or exacerbated by interleukin 13 receptor alpha 1-mediated activity comprising administering to a subject in need of treatment an effective amount of an antibody comprising(a) a heavy chain variable comprising CDR1, CDR2, and CDR3 amino acid sequences as set forth in SEQ ID NO:82, SEQ ID NO:83, and SEQ ID NO:121, respectively; and(b) a light chain variable region comprising CDR1, CDR2, and CDR3 amino acid sequences as set forth in SEQ ID NO:84, SEQ ID NO:85, and SEQ ID NO:122, respectively,thereby ameliorating the condition caused or exacerbated by interleukin 13 receptor alpha 1-mediated activity.2. The method of claim 1 , wherein the antibody comprises(a) a heavy chain variable comprising CDR1, CDR2, and CDR3 amino acid sequences as set forth in SEQ ID NO:82, SEQ ID NO:83, and SEQ ID NO:7, respectively; and(b) a light chain variable region comprising CDR1, CDR2, and CDR3 amino acid sequences as set forth in SEQ ID NO:84, SEQ ID NO:85, and SEQ ID NO:38, respectively.3. The method of claim 2 , wherein the heavy chain variable region of the antibody has the amino acid sequence as set forth in SEQ ID NO:63 and the light chain variable region of the antibody has the amino acid sequence set forth in SEQ ID NO:71.4. The method of claim 1 , wherein the condition is asthma claim 1 , allergy claim 1 , allergic rhinitis claim 1 , chronic sinusitis claim 1 , ...

Anti-ADDL monoclonal antibody and use thereof

The present invention relates to antibodies that differentially recognize multi-dimensional conformations of A-derived diffusible ligands, also known as ADDLs. The antibodies of the invention can distinguish between Alzheimer's Disease and control human brain extracts and are useful in methods of detecting ADDLs and diagnosing Alzheimer's Disease. The present antibodies also block binding of ADDLs to neurons, assembly of ADDLs, and tau phosphorylation and are there useful in methods for the preventing and treating diseases associated with soluble oligomers of amyloid 1-42.

Anti-ADDL Monoclonal Antibody and Use Thereof

The present invention relates to antibodies that differentially recognize multi-dimensional conformations of Aβ-derived diffusible ligands, also known as ADDLs. The antibodies of the invention can distinguish between Alzheimer's Disease and control human brain extracts and are useful in methods of detecting ADDLs and diagnosing Alzheimer's Disease. The present antibodies also block binding of ADDLs to neurons, assembly of ADDLS, and tau phosphorylation and are there useful in methods for the preventing and treating diseases associated with soluble oligomers of amyloid β 1-42. 112-. (canceled)13. An isolated antibody , or an antigen binding fragment of the antibody , that binds amyloid β-derived diffusible ligands comprising: (i) a CDR1 of SEQ ID NO:154,', '(ii) a CDR2 of SEQ ID NO:155, and', '(iii) a CDR3 of SEQ ID NO:2; and, '(a) a light chain variable region comprising,'} (i) a CDR1 of SEQ ID NO:156,', '(ii) a CDR2 of SEQ ID NO:157, and', '(iii) a CDR3 of SEQ ID NO:9., '(b) a heavy chain variable region comprising,'}14. The isolated antibody of claim 13 , further comprising a heavy chain constant region of SEQ ID NO:137.15. The isolated antibody of claim 13 , wherein the antibody is a monoclonal antibody.16. A pharmaceutical composition comprising the antibody or antigen binding fragment of in admixture with a pharmaceutically acceptable carrier.17. A method for attenuating binding of Aβ-derived diffusible ligands to a neuron comprising contacting the neuron with the antibody or antigen binding fragment of so that binding of Aβ-derived diffusible ligands to the neuron is attenuated.18. A method for inhibiting assembly of Aβ-derived diffusible ligands comprising contacting a sample containing amyloid β 1-42 peptides with the antibody or antigen binding fragment of thereby inhibiting assembly of Aβ-derived diffusible ligands.19. A method for inhibiting the phosphorylation of tau protein at Ser202/Thr205 comprising contacting a sample containing a tau protein with ...

ENDOTROPHIN NEUTRALIZATION AND USE THEREOF

Aspects of the present invention relate to methods and reagents for increasing chemosensitivity to platinum-based chemotherapy. In one aspect, a method of increasing chemosensitivity to platinum-based chemotherapy is provided, comprising administering to a patient in need thereof an effective amount of an endotrophin-neutralizing agent. The agent can be a monoclonal antibody, or fragment thereof, capable of binding to the C5 domain of the alpha3 chain of collagen VI. In some embodiments, the method can further include administering an effective amount of thiazolidinedione to said patient. 13-. (canceled)4. A method of treating a cancer patient comprising administering an effective amount of an antibody that binds to the C5 domain of the alpha3 chain of human collagen VI.5. The method of claim 4 , further defined as a method for inhibiting angiogenesis or increasing chemosensitivity to platinum-based chemotherapy in the patient.6. The method of claim 4 , wherein the patient has been determined to express an elevated level of endotrophin relative to control patient.7. The method claim 4 , wherein the cancer is a breast cancer or colon cancer.8. The method of claim 4 , wherein the antibody is conjugated or fused to an imaging agent or a cytotoxic agent.9. The method of claim 4 , further comprising administering at least a second anti-cancer therapy.10. The method of claim 9 , wherein the second anti-cancer therapy is a chemotherapy claim 9 , radiotherapy claim 9 , gene therapy claim 9 , surgery claim 9 , hormonal therapy claim 9 , anti-angiogenic therapy or cytokine therapy.11. The method of claim 10 , wherein the chemotherapy comprises a platinum-based chemotherapy.12. The method of claim 11 , wherein the platinum-based chemotherapy is cisplatin claim 11 , oxaliplatin or carboplatin.13. The method of claim 11 , further comprising administering thiazolidinedione to the patient.14. A monoclonal antibody claim 11 , or fragment thereof claim 11 , that binds to the C5 ...

Her3 specific monoclonal antibodies for diagnostic and therapeutic use

Isolated or recombinant anti-HER3 monoclonal antibodies are provided. In some cases, antibodies of the embodiments can be used for the detection, diagnosis and/or therapeutic treatment of human diseases, such as cancer.

EGFL6 SPECIFIC MONOCLONAL ANTIBODIES AND METHODS OF THEIR USE

Isolated or recombinant anti-EGFL6 monoclonal antibodies are provided. In some cases, antibodies of the embodiments can be used for the detection, diagnosis and/or therapeutic treatment of human diseases, such as cancer. 1. An isolated monoclonal antibody , wherein the antibody specifically binds to EGFL6 and comprises: [{'sub': 'H', '(a) a first VCDR is identical to SEQ ID NO: 4;'}, {'sub': 'H', '(b) a second VCDR is identical to SEQ ID NO: 5;'}, {'sub': 'H', '(c) a third VCDR is identical to SEQ ID NO: 6;'}, {'sub': 'L', '(d) a first VCDR is identical to SEQ ID NO: 76;'}, {'sub': 'L', '(e) a second VCDR is identical to SEQ ID NO: 77; and'}, {'sub': 'L', '(f) a third VCDR is identical to SEQ ID NO: 78;'}], '(I)'} [{'sub': 'H', '(a) a first VCDR is identical to SEQ ID NO: 10;'}, {'sub': 'H', '(b) a second VCDR is identical to SEQ ID NO:11;'}, {'sub': 'H', '(c) a third VCDR is identical to SEQ ID NO: 12;'}, {'sub': 'L', '(d) a first VCDR is identical to SEQ ID NO: 82;'}, {'sub': 'L', '(e) a second VCDR is identical to SEQ ID NO: 83; and'}, {'sub': 'L', '(f) a third VCDR is identical to SEQ ID NO: 84;'}], '(II)'} [{'sub': 'H', '(a) a first VCDR is identical to SEQ ID NO: 16;'}, {'sub': 'H', '(b) a second VCDR is identical to SEQ ID NO: 17;'}, {'sub': 'H', '(c) a third VCDR is identical to SEQ ID NO: 18;'}, {'sub': 'L', '(d) a first VCDR is identical to SEQ ID NO: 88;'}, {'sub': 'L', '(e) a second VCDR is identical to SEQ ID NO: 77; and'}, {'sub': 'L', '(f) a third VCDR is identical to SEQ ID NO: 89;'}], '(III)'} [{'sub': 'H', '(a) a first VCDR is identical to SEQ ID NO: 22;'}, {'sub': 'H', '(b) a second VCDR is identical to SEQ ID NO:23;'}, {'sub': 'H', '(c) a third VCDR is identical to SEQ ID NO: 24;'}, {'sub': 'L', '(d) a first VCDR is identical to SEQ ID NO: 93;'}, {'sub': 'L', '(e) a second VCDR is identical to SEQ ID NO: 94; and'}, {'sub': 'L', '(f) a third VCDR is identical to SEQ ID NO: 95;'}], '(IV)'} [{'sub': 'H', '(a) a first VCDR is identical to SEQ ID NO: ...

MONOCLONAL ANTIBODIES AGAINST ENDOTROPHIN AND THE USE THEREOF

Aspects of the present invention relate to methods and reagents for increasing chemosensitivity to platinum-based chemotherapy. In one aspect, a method of increasing chemosensitivity to platinum-based chemotherapy is provided, comprising administering to a patient in need thereof an effective amount of an endotrophin-neutralizing agent. The agent can be a monoclonal antibody, or fragment thereof, capable of binding to the C5 domain of the alphas chain of collagen VI. In some embodiments, the method can further include administering an effective amount of thiazolidinedione to said patient. 1. A monoclonal antibody or antibody fragment , wherein the antibody or antibody fragment is characterized by clone-paired heavy and light chain CDR sequences from Tables 1 and 2 , respectively.2. The monoclonal antibody or antibody fragment of claim 1 , wherein said antibody or antibody fragment is encoded by light and heavy chain variable sequences according to clone-paired sequences from Table 3.3. The monoclonal antibody or antibody fragment of claim 1 , wherein said antibody or antibody fragment is encoded by light and heavy chain variable sequences having at least 70% claim 1 , 80% claim 1 , or 90% identity to clone-paired sequences from Table 3.4. The monoclonal antibody or antibody fragment of claim 1 , wherein said antibody or antibody fragment is encoded by light and heavy chain variable sequences having at least 95% identity to clone-paired sequences from Table 3.5. The monoclonal antibody or antibody fragment of claim 1 , wherein said antibody or antibody fragment comprises light and heavy chain variable sequences according to clone-paired sequences from Table 4.6. The monoclonal antibody or antibody fragment of claim 1 , wherein said antibody or antibody fragment is encoded by light and heavy chain variable sequences having at least 70% claim 1 , 80% claim 1 , or 90% identity to clone-paired variable sequences from Table 4.7. The monoclonal antibody or antibody ...

HER3 SPECIFIC MONOCLONAL ANTIBODIES FOR DIAGNOSTIC AND THERAPEUTIC USE

Isolated or recombinant anti-HER3 monoclonal antibodies are provided. In some cases, antibodies of the embodiments can be used for the detection, diagnosis and/or therapeutic treatment of human diseases, such as cancer. 142-. (canceled)43. A method for treating a subject having a cancer comprising administering an effective amount of an antibody to the subject , wherein the antibody comprises:{'sub': H', 'H', 'L', 'L, '(i) a Vdomain at least about 80% identical to the Vdomain of Rab46 (SEQ ID NO: 1); hRab46H-1 (SEQ ID NO: 33); or hRab46H-2 (SEQ ID NO: 34); and a Vdomain at least about 80% identical to the Vdomain of Rab46 (SEQ ID NO: 2); hRab46L-1 (SEQ ID NO: 35); or hRab46L-2 (SEQ ID NO: 36);'}{'sub': H', 'H', 'L', 'L, '(ii) a Vdomain at least about 80% identical to the Vdomain of Rab1210 (SEQ ID NO: 3); hRab1210H-1 (SEQ ID NO: 37); or hRab1210H-2 (SEQ ID NO: 38); and a Vdomain at least about 80% identical to the Vdomain of Rab1210 (SEQ ID NO: 4); hRab1210L-1 (SEQ ID NO: 39); or hRab1210L-2 (SEQ ID NO: 40);'}{'sub': H', 'H', 'L', 'L, '(iii) a Vdomain at least about 80% identical to the Vdomain of Rab189 (SEQ ID NO: 5) and a Vdomain at least about 80% identical to the Vdomain of Rab189 (SEQ ID NO: 6); or'}{'sub': H', 'H', 'L', 'L, '(iv) a Vdomain at least about 80% identical to the Vdomain of Rab774 (SEQ ID NO: 7) and a Vdomain at least about 80% identical to the Vdomain of Rab774 (SEQ ID NO: 8).'}44. The method of claim 43 , wherein the cancer is a breast cancer claim 43 , lung cancer claim 43 , head & neck cancer claim 43 , prostate cancer claim 43 , esophageal cancer claim 43 , tracheal cancer claim 43 , skin cancer brain cancer claim 43 , liver cancer claim 43 , bladder cancer claim 43 , stomach cancer claim 43 , pancreatic cancer claim 43 , ovarian cancer claim 43 , uterine cancer claim 43 , cervical cancer claim 43 , testicular cancer claim 43 , colon cancer claim 43 , rectal cancer or skin cancer.45. The method of claim 43 , wherein the antibody is in a ...

Her3 specific monoclonal antibodies for diagnostic and therapeutic use

Isolated or recombinant anti-HER3 monoclonal antibodies are provided. In some cases, antibodies of the embodiments can be used for the detection, diagnosis and/or therapeutic treatment of human diseases, such as cancer.

Anti-lilrb antibodies and their use in detecting and treating cancer

The present disclosure is directed to antibodies binding to LILRBs and methods of detecting and treating cancer therewith.

ANTI-LILRB ANTIBODIES AND THEIR USE IN DETECTING AND TREATING CANCER

The present disclosure is directed to antibodies binding to LILRBs and methods of detecting and treating cancer therewith. 1. An isolated monoclonal antibody or an antigen-binding fragment thereof comprising a heavy chain CDR1 that is a CDR1 in SEQ ID NO: 13, SEQ ID NO: 17, SEQ ID NO: 23 or SEQ ID NO: 222,', 'a heavy chain CDR2 that is a CDR2 in SEQ ID NO: 13, SEQ ID NO: 17, SEQ ID NO: 23 or SEQ ID NO: 222, and', 'a heavy chain CDR3 that is a CDR3 in SEQ ID NO: 13, SEQ ID NO: 17, SEQ ID NO: 23 or SEQ ID NO: 222; and, '(a) a heavy chain variable region comprising the following complementary determining regions (CDRs) a light chain CDR1 that is a CDR1 in SEQ ID NO: 14, SEQ ID NO: 18, SEQ ID NO: 24 or SEQ ID NO: 223,', 'a light chain CDR2 that is a CDR2 in SEQ ID NO: 14, SEQ ID NO: 18, SEQ ID NO: 24 or SEQ ID NO: 223, and', 'a light chain CDR3 that is a CDR3 in SEQ ID NO: 14, SEQ ID NO: 18, SEQ ID NO: 24 or SEQ ID NO: 223., '(b) a light chain variable region comprising the following CDRs2. The isolated monoclonal antibody or an antigen-binding fragment thereof of claim 1 , wherein the heavy chain variable region comprises: a CDR1 comprising SEQ ID NO: 73 claim 1 , SEQ ID NO: 83 claim 1 , SEQ ID NO: 98 or SEQ ID NO: 166 claim 1 , a CDR2 comprising SEQ ID NO: 74 claim 1 , SEQ ID NO: 84 claim 1 , SEQ ID NO: 99 or SEQ ID NO: 167 claim 1 , and a CDR3 comprising SEQ ID NO: 75 claim 1 , SEQ ID NO: 85 claim 1 , SEQ ID NO: 100 or SEQ ID NO: 168.3. The isolated monoclonal antibody or an antigen-binding fragment thereof of claim 1 , wherein the light chain variable region comprises: a CDR1 comprising SEQ ID NO: 76 claim 1 , SEQ ID NO: 86 claim 1 , SEQ ID NO: 101 or SEQ ID NO: 169 claim 1 , a CDR2 comprising amino acid sequence TAS claim 1 , RAS claim 1 , EAS or SEQ ID NO: 170 claim 1 , and a CDR3 comprising SEQ ID NO: 77 claim 1 , SEQ ID NO: 87 claim 1 , SEQ ID NO: 102 or SEQ ID NO: 171.4. The isolated monoclonal antibody or an antigen-binding fragment thereof of claim 1 , ...

MULTIMERIC SARS-COV-2 BINDING MOLECULES AND USES THEREOF

This disclosure provides multimeric binding molecules that bind to SARS-CoV-2. This disclosure also provides compositions comprising the multimeric binding molecules, polynucleotides that encode the multimeric binding molecules, and host cells that can produce the binding molecules. Further this disclosure provides methods of using the multimeric binding molecules, including methods for treating and preventing coronavirus disease 2019 (COVID-19). 1. A multimeric binding molecule comprising two to six bivalent binding units , wherein each binding unit comprises two IgM or IgA heavy chain constant regions or multimerizing fragments or variants thereof each associated with a binding domain ,wherein three to twelve of the binding domains are identical immunoglobulin antigen binding domains that specifically bind to the SARS-CoV-2 spike (S) protein receptor binding domain (RBD);wherein each identical immunoglobulin antigen binding domain comprises a heavy chain variable region (VH) and a light chain variable region (VL) comprising six immunoglobulin complementarity determining regions HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3, wherein the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3, comprise, respectively, the amino acid sequencesSEQ ID NOs: 39, 40, 41, 43, 44, and 45;SEQ ID NOs: 15, 16, 17, 19, 20, and 21;SEQ ID NOs: 23, 24, 25, 27, 28, and 29;SEQ ID NOs: 31, 32, 33, 35, 36, and 37;SEQ ID NOs: 47, 48, 49, 51, 52, and 53; orSEQ ID NOs: 55, 56, 57, 59, 60, and 61;wherein the CDR regions are defined according to Kabat; and wherein the multimeric binding molecule has greater antiviral potency against SARS-CoV-2 than a bivalent reference IgG antibody comprising two of the binding domains that specifically bind to the SARS-CoV-2 S protein RBD.2. The multimeric binding molecule of claim 1 , wherein the HCDR1 claim 1 , HCDR2 claim 1 , HCDR3 claim 1 , LCDR1 claim 1 , LCDR2 claim 1 , and LCDR3 claim 1 , comprise claim 1 , respectively claim 1 , the amino acid sequences SEQ ID ...

LINKERS FOR ANTIBODY DRUG CONJUGATES

In one aspect, the present disclosure provides compounds of the formula (I): wherein the variables are as defined herein. In another aspect, the present disclosure provides compounds of the formula (V): wherein the variables are as defined herein. In another aspect, the present disclosure also provides methods of preparing the compounds disclosed herein. In another aspect, the present disclosure provides antibody drug conjugates comprising compounds of the present disclosure. In another aspect, the present disclosure also provides pharmaceutical compositions and methods of use of the compounds and anti-body drug conjugates disclosed herein. 4. The compound of any of - , wherein X is —[O(CH)]— or —[O(CHW′)]—.5. The compound of any of - , wherein Y is —[O(CH)]— or —[O(CHW′)]—.6. The compound of any of - , wherein Z is —[O(CH)]— Or —[O(CHW′)]—.7. The compound according to any one of - , wherein W′ is amino , hydroxy , halo , or mercapto.8. The compound according to any one of - , wherein W′ is alkyl , cycloalkyl , or a substituted version thereof.9. The compound of claim 8 , wherein W′ is alkylor substituted alkyl.10. The compound according to any one of - claim 8 , wherein W′ is acyl claim 8 , acyloxy claim 8 , alkylamino claim 8 , or a substituted version thereof.11. The compound of any of - claim 8 , wherein two of R claim 8 , R claim 8 , and Rare —N.12. The compound of any - claim 8 , wherein one of R claim 8 , R claim 8 , and Ris —NH claim 8 , —NHR claim 8 , or —NRR.13. The compound of claim 12 , wherein one of R claim 12 , R claim 12 , and Ris —NH.14. The compound of any of - claim 12 , wherein q is 1.15. The compound of any of - claim 12 , wherein q is 2.16. The compound of any of - claim 12 , wherein q is 3.19. The conjugate of claim 18 , wherein Xis a chemotherapeutic drug.20. The conjugate of claim 19 , wherein Xis MMAF.21. The conjugate according to any one of - claim 19 , wherein Zcomprises a polypeptide cleavable by an intracellular enzyme.22. The ...

TARGETING LILRB4 WITH CAR-T OR CAR-NK CELLS IN THE TREATMENT OF CANCER

The present disclosure provides methods and compositions for immunotherapy employing a modified T cell or NK cell comprising a chimeric LILRB4 antigen receptor (CAR) that can be administered to patients for disease (e.g., cancer) treatment. 1. A chimeric antigen receptor (CAR) protein , wherein the CAR protein binds LILRB4.2. The CAR protein of claim 1 , which has a binding affinity to LILRB4 (ECas measured by ELISA) below 1 nM claim 1 , but greater than zero.3. The CAR protein of claim 2 , wherein the binding affinity is 0.05-0.99 nM claim 2 , 0.05-0.9 nM claim 2 , 0.05-0.8 nM claim 2 , 0.05-0.7 nM claim 2 , 0.05-0.6 nM claim 2 , 0.05-0.5 nM claim 2 , 0.05-0.4 nM claim 2 , 0.05-0.3 nM claim 2 , 0.05-0.2 nM claim 2 , or 0.05-0.1 nM.4. The CAR protein of claim 1 , comprising (i) VH CDRs 1-3 of SEQ ID NOS: 1-3 and VL CDRs 1-3 of SEQ ID NOS: 4-6 claim 1 , or (ii) VH CDRs 1-3 of SEQ ID NOS: 11-13 and VL CDRs 1-3 of SEQ ID NOS: 14-16.5. The CAR protein of claim 1 , comprising an VH amino acid sequence at least 90% identical to SEQ ID NO: 7 and a VL amino acid sequence at least 85% claim 1 , 90% claim 1 , 95% or 99% identical to SEQ ID NO: 9.6. The CAR protein of claim 1 , comprising an VH amino acid sequence at least 90% identical to SEQ ID NO: 7 and a VL amino acid sequence identical to SEQ ID NO: 9.7. The CAR protein of claim 1 , comprising an VH amino acid sequence at least 90% identical to SEQ ID NO: 17 and a VL amino acid sequence at least 85% claim 1 , 90% claim 1 , 95% or 99% identical to SEQ ID NO: 19.8. The CAR protein of claim 1 , comprising an VH amino acid sequence at least 90% identical to SEQ ID NO: 17 and a VL amino acid sequence identical to SEQ ID NO: 19.9. The CAR protein of claim 1 , comprising an amino acid sequence at least 85% claim 1 , 90% claim 1 , 95% or 99% identical to SEQ ID NOS: 21-23 claim 1 , 31-33 claim 1 , or 40-41.10. The CAR protein of claim 1 , comprising an amino acid sequence identical to SEQ ID NOS: 21-23 claim 1 , 31-33 claim 1 , ...

ENDOTROPHIN NEUTRALIZATION AND USE THEREOF

Aspects of the present invention relate to methods and reagents for increasing chemosensitivity to platinum-based chemotherapy. In one aspect, a method of increasing chemosensitivity to platinum-based chemotherapy is provided, comprising administering to a patient in need thereof an effective amount of an endotrophin-neutralizing agent. The agent can be a monoclonal antibody, or fragment thereof, capable of binding to the C5 domain of the alpha3 chain of collagen VI. In some embodiments, the method can further include administering an effective amount of thiazolidinedione to said patient.

ANTI-LAIR1 ANTIBODIES AND THEIR USES

The present disclosure is directed to antibodies binding to LAIR 1 and their treating cancer, inflammation, immune-related diseases or transplantation. 1. An isolated monoclonal antibody or an antigen binding fragment thereof , which , when bound to LAIR1 , modulates the activity of LAIR1.2. The isolated monoclonal antibody or an antigen binding fragment thereof of claim 1 , which activates LAIR1.3. The isolated monoclonal antibody or an antigen binding fragment thereof of claim 1 , which suppresses the activation of LAIR1.4. The isolated monoclonal antibody or an antigen binding fragment thereof of claim 1 , which specifically blocks binding of Collagen Ito LAIR1.5. The isolated monoclonal antibody or an antigen binding fragment thereof of claim 1 , which specifically binds to an epitope contained within the Ig domain of LAIR1 (amino acid residues 25-121).6. The isolated monoclonal antibody or an antigen binding fragment thereof of claim 5 , wherein the epitope is contained within the amino acid residues 25-47 claim 5 , 53-81 claim 5 , 88-96 and/or 102-119 of LAIR1.7. The isolated monoclonal antibody or an antigen binding fragment thereof of claim 5 , wherein the epitope is contained within the amino acid residues 30-34 claim 5 , 45-47 and/or 88-89 of LAIR1.8. The isolated monoclonal antibody or an antigen binding fragment thereof of claim 5 , wherein the epitope is contained within the amino acid residues 37-41 claim 5 , 116-119 claim 5 , 98-105 claim 5 , 59-63 and/or 66-71 of LAIR1.9. The isolated monoclonal antibody or an antigen binding fragment thereof of claim 5 , wherein the epitope comprises amino acid residues 30-34 claim 5 , 37-41 claim 5 , 45-47 claim 5 , 59-63 claim 5 , 66-71 claim 5 , 88-89 claim 5 , 98-105 claim 5 , 108-110 or 116-119 of LAIR1.10. The isolated monoclonal antibody or an antigen binding fragment thereof of claim 5 , wherein the epitope comprises amino acid residues 35-36 claim 5 , 44 claim 5 , 53-56 claim 5 , 64-65 claim 5 , 73-81 claim ...

High affinity antibody antagonists of interleukin-13 receptor alpha 1

High affinity antibody antagonists of human interleukin-13 receptor alpha 1 are disclosed. The antibody molecules are effective in the inhibition of IL-13Rα1-mediated activities and, accordingly, present desirable antagonists for the use in the treatment of conditions associated with hIL-13Rα1 activity. The present disclosure also provides nucleic acid encoding said antibody molecules, vectors, host cells, and compositions comprising the antibody molecules. Methods of using the antibody molecules for inhibiting or antagonizing IL-13Rα1-mediated activities are also disclosed.

Anti-il-13r.alpha.1 antibodies and their uses thereof

Antibody antagonists of human interleukin-13 receptor alpha 1 which bind to hIL-13R.alpha.l through domain 3 of the extracellular region of the receptor and inhibit IL-13 receptor-mediated signaling by IL-13 are disclosed herein. These antibodies have uses inter alia in the treatment or prevention of IL-13-related disorders and diseases. The present invention also discloses nucleic acid encoding said antibody molecules, vectors, host cells, and compositions comprising the antibody molecules. Methods of using the antibody molecules for inhibiting or antagonizing hIL-13R.alpha.l- mediated activities are also disclosed.

Interleukin alpha 1 receptor high affinity antibody antagonists

Un anticuerpo aislado que se une al receptor alfa 1 de interleucina 13 humana, en el que (A) el anticuerpo aislado comprende: (i) una región variable de la cadena pesada que tiene una secuencia de aminoácidos seleccionada del grupo que consiste en SEC ID Nº: 45, SEC ID Nº: 51, SEC ID Nº: 55 y SEC ID Nº: 63; y (ii) una región variable de la cadena ligera que tiene una secuencia de aminoácidos seleccionada del grupo que consiste en SEC ID Nº: 49, SEC ID Nº: 71 y SEC ID Nº: 75; o (B) el anticuerpo aislado presenta una constante de disociación en equilibrio (KD) inferior a 100 pM con receptor alfa 1 de interleucina 13 humana, como se ha determinado por resonancia de plasmones superficiales usando una proteína que consiste en la secuencia de aminoácidos de SEC ID Nº: 103, y antagoniza la actividad mediada por el receptor alfa 1 de interleucina 13 humana, en el que la región variable de la cadena pesada de dicho anticuerpo comprende una secuencia de aminoácidos como se expone en SEC ID Nº: 63 o una secuencia con al menos el 95 % de identidad con la secuencia expuesta en SEC ID Nº: 63; y una región variable de la cadena ligera de dicho anticuerpo comprende una secuencia de aminoácidos como se expone en SEC ID Nº: 71 o una secuencia con al menos el 95 % de identidad con la secuencia expuesta en SEC ID Nº: 71. An isolated antibody that binds to the human interleukin 13 alpha 1 receptor, in which (A) the isolated antibody comprises: (i) a heavy chain variable region having an amino acid sequence selected from the group consisting of SEQ ID No.: 45, SEQ ID NO: 51, SEQ ID NO: 55 and SEQ ID NO: 63; and (ii) a variable region of the light chain having an amino acid sequence selected from the group consisting of SEQ ID NO: 49, SEQ ID NO: 71 and SEQ ID NO: 75; or (B) the isolated antibody has an equilibrium dissociation constant (KD) of less than 100 pM with human interleukin 13 alpha 1 receptor, as determined by surface plasmon resonance using a protein consisting of the amino ...

Novel lilrb4 antibodies and uses thereof

The present disclosure provides an isolated monoclonal antibody or an antigen-binding fragment thereof that binds specifically to leukocyte immunoglobulin-like receptor 4 (LILRB4). In certain embodiments, the antibody or antigen-binding fragment, when bound to LILRB4, modulates the activation of LILRB4. In certain embodiments, the antibody or antigen-binding fragment, when bound to LILRB4, activates LILRB4. In certain embodiments, the antibody or antigen binding fragment, when bound to LILRB4, suppresses activation of LILRB4. In certain embodiments, the antibody or antigen-binding fragment, when bound to LILRB4, specifically blocks binding of ApoE to LILRB4. In another aspect, there is provided a method of treating or ameliorating the effects of a cancer in a subject, comprising administering to the subject a therapeutically effective amount of the antibody or an antigen-binding fragment thereof or an engineered cell as provided herein.

Cmv neutralizing antigen binding proteins

Egfl6 specific monoclonal antibodies and methods of their use

Isolated or recombinant anti-EGFL6 monoclonal antibodies are provided. In some cases, antibodies of the embodiments can be used for the detection, diagnosis and/or therapeutic treatment of human diseases, such as cancer.

Anti-addl antibodies and uses thereof

The present invention relates to antibodies that differentially recognize multi-dimensional conformations of A.beta.-derived diffusible ligands, also known as ADDLs. The antibodies of the invention can distinguish between Alzheimer's Disease and control human brain extracts and are useful in methods of detecting ADDLs and diagnosing Alzheimer's Disease. The present antibodies also block binding of ADDLs to neurons, assembly of ADDLs, and tauphosphorylation and are there useful in methods for the preventing and treating diseases associated with soluble oligomers of amyloid .beta. 1-42.

Anti-lair1 antibodies and their uses

The present disclosure is directed to antibodies binding to LAIR 1 and their treating cancer, inflammation, immune-related diseases or transplantation.

Anti-ADDL antibodies and uses thereof

Novel lilrb4 antibodies and uses thereof

The present disclosure provides an isolated monoclonal antibody or an antigen-binding fragment thereof that binds specifically to leukocyte immunoglobulin-like receptor 4 (LILRB4). In certain embodiments, the antibody or antigen-binding fragment, when bound to LILRB4, modulates the activation of LILRB4. In certain embodiments, the antibody or antigen-binding fragment, when bound to LILRB4, activates LILRB4. In certain embodiments, the antibody or antigen binding fragment, when bound to LILRB4, suppresses activation of LILRB4. In certain embodiments, the antibody or antigen-binding fragment, when bound to LILRB4, specifically blocks binding of ApoE to LILRB4. In another aspect, there is provided a method of treating or ameliorating the effects of a cancer in a subject, comprising administering to the subject a therapeutically effective amount of the antibody or an antigen-binding fragment thereof or an engineered cell as provided herein.

Anti-addl antibodies and uses thereof

Egfl6 specific monoclonal antibodies and methods of their use

High affinity antibody antagonist of interleukin-13 receptor alpha 1

【課題】ヒトインターロイキン-13レセプターアルファ1の高親和性抗体アンタゴニストが開示される。本発明はまた、前記抗体分子をコードする核酸、ベクター、宿主細胞、および前記抗体分子を含む組成物を開示する。IL-13Rα1仲介活性の阻害または拮抗のために抗体分子を使用する方法もまた開示される。 【解決手段】（a）重鎖可変領域が、それぞれ特定の配列のCDR1、CDR2およびCDR3アミノ酸配列を含み；さらに（b）軽鎖可変領域が、それぞれ他の特定の配列のCDR1、CDR2およびCDR3アミノ酸配列を含む、ヒトインターロイキン13レセプターアルファ1と結合する単離抗体。 【選択図】なし

Trem2 antigen binding proteins and uses thereof

The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, antibodies, antibody fragments etc., that specifically bind a TREM2 protein or a TREM2 protein epitope, e.g., a mammalian TREM2 or human TREM2, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.

High affinity antibody antagonists of interleukin-13 receptor alpha 1

High affinity antibody antagonists of human interleukin-13 receptor alpha 1 are disclosed. The antibody molecules are effective in the inhibition of IL-13R.alpha.l- mediated activities and, accordingly, present desirable antagonists for the use in the treatment of conditions associated with hIL-13R.alpha.l activity. The present invention also discloses nucleic acid encoding said antibody molecules, vectors, host cells, and compositions comprising the antibody molecules. Methods of using the antibody molecules for inhibiting or antagonizing IL-13R.alpha.l-mediated activities are also disclosed.

Anti-IL-13Ralfa1 antibodies and their applications

Antibodies to coronavirus spike protein and methods of use thereof

Provided herein are antibodies binding to Coronavirus S protein and the uses of the antibodies in detecting and treating Coronavirus infection, such as COVID-19.

Anti-addl monoclonal antibody and use thereof

The present invention relates to antibodies that -differentially -recognize- -multi- dimensional conformations- of- Aβ- derived diffusible ligands, also known as ADDLs. The antibodies of the invention can distinguish between Alzheimer's Disease and control human brain extracts and are useful in methods of detecting ADDLs and diagnosing Alzheimer's Disease. The present antibodies also block binding of ADDLs to neurons, assembly of ADDLS, and tau phosphorylation and are there useful in methods for the preventing and treating diseases associated with soluble oligomers of amyloid β 1-42.

Targeting lilrb4 with car-t or car-nk cells in the treatment of cancer

Anti-ADDL antibodies and uses thereof

Abstract: The present invention relates to antibodies that differentially recognize multi-dimensional conformations of AP-derived diffusible ligands, also known as ADDLs. The antibodies of the 5 invention can distinguish between Alzheimer's Disease and control human brain extracts and are useful in methods of detecting ADDLs and diagnosing Alzheimer's Disease. The present antibodies also block binding of ADDLs to neurons, assembly of ADDLs, and tauphosphorylation and are there useful in methods .0 for the preventing and treating diseases associated with soluble oligomers of amyloid @ 1-42.

Anti-ADDL antibodies and uses thereof

Monoclonal anti-ADDL antibody and its use

SAMMENDRAG Den foreliggende oppfinnelsen vedrører antistoffer som differensielt gjenkjenner multidimensjonale konformasjoner for AP-avledede diffunderbare ligander, også kjent som ADDL-typer. Antistoffene ifølge oppfinnelsen kan skille mellom hjerneekstrakter med Alzheimers sykdom og humane kontrollhjerneekstrakter og er nyttige i fremgangsmåter for å påvise ADDL-typer og å diagnostisere Alzheimers sykdom. De foreliggende antistoffene blokkerer også binding av ADDL-typer til nevroner, sammensetning av ADDL-typer og taufosforylering og er derfor nyttige fremgangsmåter for forebygging og behandling av sykdommer som er assosiert med løselige oligomerer av amyloid ß1-42.

Therapeutic agents and uses thereof

The present disclosure relates generally to therapeutic agents and related uses thereof, including, agents for reducing leptin in a patient or subject and methods of treatment thereof. The therapeutic agents can comprise (without limitation), an antibody or specific binding fragment thereof, a leptin antagonist, a leptin targeting antisense oligonucleotide, a leptin targeting small interfering RNA (siRNA), a leptin targeting short hairpin RNA (shRNA), and/or a gene editing composition directed to at least one target sequence of a leptin polynucleotide. The therapeutic agents can be used in various methods of treatment, including (without limitation), treating liver fibrosis, cancer, inducing or maintaining weight loss, reducing or preventing weight gain, and increasing insulin sensitivity, among others.

Anti-addl antibodies and uses thereof

Linkers for antibody drug conjugates

In one aspect, the present disclosure provides compounds of the formula (I): wherein the variables are as defined herein. In another aspect, the present disclosure provides compounds of the formula (V): wherein the variables are as defined herein. In another aspect, the present disclosure also provides methods of preparing the compounds disclosed herein. In another aspect, the present disclosure provides antibody drug conjugates comprising compounds of the present disclosure. In another aspect, the present disclosure also provides pharmaceutical compositions and methods of use of the compounds and anti-body drug conjugates disclosed herein.

Novel lilrb4 antibodies and uses thereof

Monoclonal antibodies against endotrophin and the use thereof

Novel ddr1 antibodies and uses thereof

The present disclosure relates to antibodies binding to tumor discoidin domain receptor 1 (DDR1) and the uses of the antibodies in detecting and treating cancer. Thus, in one aspect, the present disclosure provides an isolated monoclonal antibody or an antigen-binding fragment thereof that binds specifically to DDR1. In certain embodiments, the antibody or antigen-binding fragment, when bound to DDR1, modulates the activity of DDR1, i.e., suppresses DDR1.

Antigen-binding proteins targeting s. aureus orf0657n

The present invention features antigen binding proteins that bind to a region found to have an epitope that can be targeted to provide protection against S. aureus infection. The region is designated herein as the "CS-D7" target region. The CS-D7 target region provides an S. aureus ORF0657n epitope that can be targeted to reduce the likelihood or severity of an S. aureus infection.

ANTI-IL-13Rα1 ANTIBODIES AND THEIR USES THEREOF

Antibody antagonists of human interleukin-13 receptor alpha 1 which bind to hIL-13Rαl through domain 3 of the extracellular region of the receptor and inhibit IL-13 receptor-mediated signaling by IL-13 are disclosed herein. These antibodies have uses inter alia in the treatment or prevention of IL-13-related disorders and diseases. The present invention also discloses nucleic acid encoding said antibody molecules, vectors, host cells, and compositions comprising the antibody molecules. Methods of using the antibody molecules for inhibiting or antagonizing hIL-13Rαl- mediated activities are also disclosed.

Antigen-binding proteins targeting S. aureus ORF0657n

Antibody antagonists of interleukin-13 receptor .alpha.1

Antibody antagonists of human interleukin-13 receptor alpha 1 are disclosed. The antibody molecules are useful in the inhibition of IL- 13R.alpha.1 -mediated activities and, accordingly, present desirable antagonists for the use in the treatment of conditions associated with hIL-13R.alpha.1 activity. The present invention also discloses nucleic acid encoding said antibody molecules, vectors, host cells, and compositions comprising the antibody molecules. Methods of using the antibody molecules for inhibiting or antagonizing IL-13R.alpha.1-mediated activities are also disclosed.

Antibodies specific for dkk-1

Antibodies specific for Dkk-1, an inhibitor of the osteoanabolic Wnt/LRP5 signaling pathway, are described. The antibodies, which inhibit binding of Dkk-1 to LRP5, are useful in compositions for stimulating bone growth, in particular, compositions for treating bone disorders which result in a loss in bone, for example, osteoporosis.

Anti-LAIR1 antibodies and their uses

The present disclosure is directed to antibodies binding to LAIR 1 and their treating cancer, inflammation, immune-related diseases or transplantation.

Egfl6 specific monoclonal antibodies and methods of their use

Anti-lair1 antibodies and their uses

The present disclosure is directed to antibodies binding to LAIR 1 and their treating cancer, inflammation, immune-related diseases or transplantation.

Targeting lilrb4 with car-t or car-nk cells in the treatment of cancer

The present disclosure provides methods and compositions for immunotherapy employing a modified T cell or NK cell comprising a chimeric LILRB4 antigen receptor (CAR) that can be administered to patients for disease (e.g., cancer) treatment.

Anti-lilrb antibodies and their use in detecting and treating cancer

The present disclosure is directed to antibodies binding to LILRBs and methods of detecting and treating cancer therewith.

Cmv neutralizing antigen binding proteins

The present invention is directed to antigen binding proteins including, but not limited to, monoclonal antibodies and antigen binding fragments thereof, that specifically bind to and preferably neutralize human cytomegalovirus (CMV). Also encompassed by the invention are antigen binding proteins that have been humanized. The antigen binding proteins of the invention are useful as a therapeutic agent for treating and/or preventing CMV infections in a patient in need thereof.

Anti-ADDL antibodies and uses thereof

Abstract: The present invention relates to antibodies that differentially recognize multi-dimensional conformations of AP-derived diffusible ligands, also known as ADDLs. The antibodies of the 5 invention can distinguish between Alzheimer's Disease and control human brain extracts and are useful in methods of detecting ADDLs and diagnosing Alzheimer's Disease. The present antibodies also block binding of ADDLs to neurons, assembly of ADDLs, and tauphosphorylation and are there useful in methods .0 for the preventing and treating diseases associated with soluble oligomers of amyloid @ 1-42.

Methods for identifying lilrb-blocking antibodies

Provided herein are methods and compositions for the identification of modulators of LILRB3 activation. Also provided herein are methods of treating cancer comprising the administration of an inhibitor LILRB3 activation. Also provided are methods of treating autoimmune disease or inhibiting the onset of transplant rejection or treating an inflammatory disorder comprising administering an agonist of LILRB3 activation to a subject.

Anti-il-13r.alpha.1 antibodies and their uses thereof

Antibody antagonists of human interleukin-13 receptor alpha 1 which bind to hIL-13R.alpha.l through domain 3 of the extracellular region of the receptor and inhibit IL-13 receptor-mediated signaling by IL-13 are disclosed herein. These antibodies have uses inter alia in the treatment or prevention of IL-13-related disorders and diseases. The present invention also discloses nucleic acid encoding said antibody molecules, vectors, host cells, and compositions comprising the antibody molecules. Methods of using the antibody molecules for inhibiting or antagonizing hIL-13R.alpha.l- mediated activities are also disclosed.

Anti-addl monoclonal antibody and use thereof

The present invention relates to antibodies that -differentially -recognize- -multi- dimensional conformations- of- A.beta.- derived diffusible ligands, also known as ADDLs. The antibodies of the invention can distinguish between Alzheimer's Disease and control human brain extracts and are useful in methods of detecting ADDLs and diagnosing Alzheimer's Disease. The present antibodies also block binding of ADDLs to neurons, assembly of ADDLS, and tau phosphorylation and are there useful in methods for the preventing and treating diseases associated with soluble oligomers of amyloid .beta. 1-42.

Anti-ADDL antibodies and uses thereof

Disclosed is an antibody that differentially recognizes multi-dimensional conformations of Abeta-derived diffusible ligands, also known as ADDLs. The antibody can distinguish between Alzheimer's Disease and control human brain extracts and is useful in methods of detecting ADDLs and diagnosing Alzheimer's Disease. The antibody can also block binding of ADDLs to neurons, assembly of ADDLs, and tauphosphorylation and is useful in methods for preventing and treating diseases associated with soluble oligomers of amyloid beta 1-42.

Tfr antigen binding proteins and uses thereof

The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, antibodies, antibody fragments, etc., that specifically bind a TfR protein, e.g., a mammalian TfR or human TfR, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.

Methods for identifying lilrb-blocking antibodies

Provided herein are methods and compositions for the identification of modulators of ApoE-induced LILRB activation. Also provided herein are methods of treating cancer comprising the administration of an inhibitor of ApoE-induced LILRB activation. Also provided are methods of treating autoimmune disease or inhibiting the onset of transplant rejection or treating an inflammatory disorder comprising administering an agonist of ApoE-induced LILRB activation to a subject.

Novel DDR1 antibodies and uses thereof

The present disclosure relates to antibodies binding to tumor discoidin domain receptor 1 (DDR1) and the uses of the antibodies in detecting and treating cancer. Thus, in one aspect, the present disclosure provides an isolated monoclonal antibody or an antigen-binding fragment thereof that binds specifically to DDR1. In certain embodiments, the antibody or antigen-binding fragment, when bound to DDR1, modulates the activity of DDR1, i.e., suppresses DDR1.

Targeting lilrb4 with car-t or car-nk cells in the treatment of cancer

The present disclosure provides methods and compositions for immunotherapy employing a modified T cell or NK cell comprising a chimeric LILRB4 antigen receptor (CAR) that can be administered to patients for disease (e.g., cancer) treatment.

Nmes1 antibodies and methods of use thereof

Provided herein are methods for treating cancer, such as breast cancer, by administering an inhibitor of NMES1. Further provided herein are NMES1 monoclonal antibodies which may be used to detect or treat cancer.

Therapeutic agents and uses thereof

The present disclosure relates generally to therapeutic agents and related uses thereof, including, agents for reducing leptin in a patient or subject and methods of treatment thereof. The therapeutic agents can comprise (without limitation), an antibody or specific binding fragment thereof, a leptin antagonist, a leptin targeting antisense oligonucleotide, a leptin targeting small interfering RNA (siRNA), a leptin targeting short hairpin RNA (shRNA), and/or a gene editing composition directed to at least one target sequence of a leptin polynucleotide. The therapeutic agents can be used in various methods of treatment, including (without limitation), treating liver fibrosis, cancer, inducing or maintaining weight loss, reducing or preventing weight gain, and increasing insulin sensitivity, among others.

Methods for identifying lilrb ligands and blocking antibodies

Disclosed are the identification of multiple proteins that can bind to LILR receptors, based on which a screening system for LILR antagonist and blocking antibodies has been developed.

Methods for identifying lilrb-blocking antibodies

Provided herein are methods and compositions for the identification of modulators of LILRB3 activation. Also provided herein are methods of treating cancer comprising the administration of an inhibitor LILRB3 activation. Also provided are methods of treating autoimmune disease or inhibiting the onset of transplant rejection or treating an inflammatory disorder comprising administering an agonist of LILRB3 activation to a subject.

Assays for detection and quantitation of human endotrophin

The present disclosure is directed to antibodies binding to human endotrophin and methods for use of such antibodies to detect endotrophin in human samples.

Antibodies to coronavirus spike protein and methods of use thereof

Provided herein are antibodies binding to Coronavirus S protein and the uses of the antibodies in detecting and treating Coronavirus infection, such as COVID-19.

EGFL6 specific monoclonal antibodies and methods of their use

Isolated or recombinant anti-EGFL6 monoclonal antibodies are provided. In some cases, antibodies of the embodiments can be used for the detection, diagnosis and/or therapeutic treatment of human diseases, such as cancer.

Anti-lilrb antibodies and their use in detecting and treating cancer

The present disclosure is directed to antibodies binding to LILRBs and methods of detecting and treating cancer therewith.

Anti-lilrb antibodies and their use in detecting and treating cancer

The present disclosure is directed to antibodies binding to LILRBs and methods of detecting and treating cancer therewith.

Methods for identifying lilrb ligands and blocking antibodies

Disclosed are the identification of multiple proteins that can bind to LILR receptors, based on which a screening system for LILR antagonist and blocking antibodies has been developed.

Lilrb2-specific monoclonal antibodies and methods of their use

Isolated or recombinant anti- LILRB2 monoclonal antibodies are provided. In some embodiments, the antibodies herein can be used for the detection, diagnosis and/or therapeutic treatment of human diseases, such as Alzheimer's Disease. In further aspects, the LILRB2-binding antibodies can affect cellular signaling mediated through at least the oA and PS-mediated TREM2 and LILRB2 co-ligation signaling pathway and can be used to modulate microglia function.

Her3 specific monoclonal antibodies for diagnostic and therapeutic use

Isolated or recombinant anti-HER3 monoclonal antibodies are provided. In some cases, antibodies of the embodiments can be used for the detection, diagnosis and/or therapeutic treatment of human diseases, such as cancer.

Connexin (Cx) 43 hemichannel-binding antibodies and uses thereof

Antibodies that bind to connexin 43 hemichannels and inhibit, or activate, channel opening are provided. In certain aspects, methods for detecting or treating cancers with antibodies that activate Cx43 channel opening are also provided. Likewise, methods for treating inflammatory diseases (e.g., osteoarthritis) and neurological injuries (e.g., spinal cord injury) with antibodies that inhibit Cx43 channel opening are provided.

Methods for identifying lilrb-blocking antibodies

Provided herein are methods and compositions for the identification of modulators of LILRB3 activation. Also provided herein are methods of treating cancer comprising the administration of an inhibitor LILRB3 activation. Also provided are methods of treating autoimmune disease or inhibiting the onset of transplant rejection or treating an inflammatory disorder comprising administering an agonist of LILRB3 activation to a subject.

Therapeutic agents and uses thereof

The present disclosure relates generally to therapeutic agents and related uses thereof, including, agents for reducing leptin in a patient or subject and methods of treatment thereof. The therapeutic agents can comprise (without limitation), an antibody or specific binding fragment thereof, a leptin antagonist, a leptin targeting antisense oligonucleotide, a leptin targeting small interfering RNA (siRNA), a leptin targeting short hairpin RNA (shRNA), and/or a gene editing composition directed to at least one target sequence of a leptin polynucleotide. The therapeutic agents can be used in various methods of treatment, including (without limitation), treating liver fibrosis, cancer, inducing or maintaining weight loss, reducing or preventing weight gain, and increasing insulin sensitivity, among others.

Novel lilrb4 antibodies and uses thereof

Tripeptide linkers and methods of use thereof

Provided herein are peptide linkers which may be used to prepare drug conjugates, drug conjugates prepared using these linkers, and compositions and methods of treatment thereof.